Popular weight-loss medications including Ozempic and Wegovy contain a drug that seems to decrease cravings for food and drugs – and now there’s evidence that it might make exercise less rewarding, to

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended – which means compounding of the medicine must stop.

Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance plans, a new survey shows.

The microbiome undergoes a radical transformation during massive weight loss. The result has a profound impact on your health.

A growing number of employers are considering covering the blockbuster weight-loss drugs, several surveys show. Workers will learn whether they’ll gain such coverage for the coming year during open enrollment,

Expanding Medicare to cover weight loss drugs would cost $35 billion over eight years, according to a new report from the Congressional Budget Office (CBO). In its estimates released Tuesday, CBO

Less than a fifth of large employers in the U.S. include coverage for the popular but pricey weight loss drugs Wegovy and Zepbound, a KFF survey finds.

Compounding pharmacies are suing the Food and Drug Administration so they can keep making imitation versions of popular—and lucrative—tirzepatide drugs, namely knockoffs of Mounjaro for diabetes and Zepbound for weight loss.

With the shortage over, compounding pharmacies are no longer allowed to produce the popular weight loss drugs.